Literature DB >> 11053486

Glomerular permselectivity at the onset of nephropathy in type 2 diabetes mellitus.

Kevin V Lemley1,2, Kristina Blouch2, Isha Abdullah2, Derek B Boothroyd3, Peter H Bennett4, Bryan D Myers2, Robert G Nelson4.   

Abstract

The development of microalbuminuria in individuals with type 2 diabetes mellitus is associated with a 10-fold increase in the risk of progression to overt nephropathy and eventual end-stage renal failure. The present study reports long-term (up to 8 yr) follow-up of 43 Pima Indians with type 2 diabetes detected on screening to have microalbuminuria. The natural history of albuminuria in these individuals included progression to overt proteinuria (urinary albumin excretion > or = 300 mg/d) in half of the participants by 7 yr of follow-up. The size selectivity of the glomerular barrier was also investigated using dextran sieving and pore theory. Whereas a comparison group of macroalbuminuric Pima Indians had an excess of large pores that served as a macromolecular "shunt," individuals with microalbuminuria had a shunt size no different from long-term diabetic, normoalbuminuric control subjects. An abrupt transition from little or no relationship to a highly significant and positive relationship between increasing albuminuria and shunt size occurred at an albumin-to-creatinine ratio of approximately 3000 mg/g. Shunt size in macroalbuminuric individuals correlated with the extent of foot process broadening. Podocyte foot processes in microalbuminuric participants were not different from those in control subjects. In conclusion, although microalbuminuria in type 2 diabetic Pima Indians often heralds progressive glomerular injury, it is not the result of defects in the size permselectivity of the glomerular barrier but rather of changes in either glomerular charge selectivity or tubular handling of filtered proteins or of a combination of these two factors.

Entities:  

Mesh:

Year:  2000        PMID: 11053486     DOI: 10.1681/ASN.V11112095

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  34 in total

1.  High glucose causes dysfunction of the human glomerular endothelial glycocalyx.

Authors:  A Singh; V Fridén; I Dasgupta; R R Foster; G I Welsh; J E Tooke; B Haraldsson; P W Mathieson; S C Satchell
Journal:  Am J Physiol Renal Physiol       Date:  2010-10-27

2.  An Extended Minimal Physiologically Based Pharmacokinetic Model: Evaluation of Type II Diabetes Mellitus and Diabetic Nephropathy on Human IgG Pharmacokinetics in Rats.

Authors:  Gurkishan S Chadha; Marilyn E Morris
Journal:  AAPS J       Date:  2015-08-15       Impact factor: 4.009

3.  Investigation of the influence of nephropathy on monoclonal antibody disposition: a pharmacokinetic study in a mouse model of diabetic nephropathy.

Authors:  Frank A Engler; Bo Zheng; Joseph P Balthasar
Journal:  Pharm Res       Date:  2013-11-08       Impact factor: 4.200

Review 4.  When to initiate ACEI/ARB therapy in patients with type 1 and 2 diabetes.

Authors:  Kevin V Lemley
Journal:  Pediatr Nephrol       Date:  2010-03-30       Impact factor: 3.714

Review 5.  Proteinuria should be used as a surrogate in CKD.

Authors:  Paolo Cravedi; Piero Ruggenenti; Giuseppe Remuzzi
Journal:  Nat Rev Nephrol       Date:  2012-03-06       Impact factor: 28.314

6.  Increased lipogenesis and impaired β-oxidation predict type 2 diabetic kidney disease progression in American Indians.

Authors:  Farsad Afshinnia; Viji Nair; Jiahe Lin; Thekkelnaycke M Rajendiran; Tanu Soni; Jaeman Byun; Kumar Sharma; Patrice E Fort; Thomas W Gardner; Helen C Looker; Robert G Nelson; Frank C Brosius; Eva L Feldman; George Michailidis; Matthias Kretzler; Subramaniam Pennathur
Journal:  JCI Insight       Date:  2019-11-01

7.  Effect of Type 2 Diabetes Mellitus and Diabetic Nephropathy on IgG Pharmacokinetics and Subcutaneous Bioavailability in the Rat.

Authors:  Gurkishan S Chadha; Marilyn E Morris
Journal:  AAPS J       Date:  2015-04-30       Impact factor: 4.009

8.  Podocyte detachment in type 2 diabetic nephropathy.

Authors:  E Jennifer Weil; Kevin V Lemley; Berne Yee; Tracy Lovato; Meghan Richardson; Bryan D Myers; Robert G Nelson
Journal:  Am J Nephrol       Date:  2011-06-10       Impact factor: 3.754

Review 9.  Where does albuminuria come from in diabetic kidney disease?

Authors:  Wayne D Comper; Leileata M Russo
Journal:  Curr Diab Rep       Date:  2008-12       Impact factor: 4.810

10.  Predictive power of sequential measures of albuminuria for progression to ESRD or death in Pima Indians with type 2 diabetes.

Authors:  Meda E Pavkov; William C Knowler; Robert L Hanson; Peter H Bennett; Robert G Nelson
Journal:  Am J Kidney Dis       Date:  2008-03-20       Impact factor: 8.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.